Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343674 | 0.94 | POLB (0.45) | POLBABL1RIN1 | |
| SCHEMBL6275167 | 0.90 | POLB (0.41) | POLBABL1RIN1 | |
| SCHEMBL26451579 | 0.89 | POLB (0.39) | POLBABL1RIN1 | |
| SCHEMBL15301590 | 0.89 | POLB (0.39) | POLBABL1RIN1 | |
| SCHEMBL26451573 | 0.89 | POLB (0.39) | POLBABL1RIN1 | |
| SCHEMBL31380110 | 0.89 | POLB (0.39) | POLBABL1RIN1 | |
| SCHEMBL1539812 | 0.83 | POLB (0.46) | POLBABL1RIN1 | |
| SCHEMBL8583477 | 0.83 | P2RY6 (0.31) | — | |
| SCHEMBL21901420 | 0.83 | POLB (0.39) | POLBABL1RIN1 | |
| SCHEMBL6574062 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3943500-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | Agilent Technologies, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3137478-B1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2020-01-30 | — | — | US | disclosed |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2019-06-27 | — | — | US | disclosed |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2019-04-09 | — | — | US | disclosed |
| US-10059986-B2 | Reversible terminator molecules and methods of their use | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2015168461-A2 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140242579-A1 | REVERSIBLE TERMINATOR MOLECULES AND METHODS OF THEIR USE | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION | 2014-08-28 | — | — | US | disclosed |
| US-8748405-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2011-03-24 | — | — | US | disclosed |
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2005115410-A2 | CONTEXT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | POLB 5/4885ABL1 3420/4885RIN1 4020/4885 |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | POLB 5/4885ABL1 3420/4885RIN1 4020/4885 |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | POLB 5/4885ABL1 3420/4885RIN1 4020/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | POLB 2502/4885ABL1 841/4885RIN1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.